Scintilla Pharmaceuticals

Scintilla Pharmaceuticals is currently a subsidiary of Sorrento Therapeutics. Scintilla's lead program is RTX for the treatment of opiate refractory cancer pain. The RTX program has been tested successfully in a Phase 1 - 2 clinical trial, and is scheduled to commence Phase 2 clinical trials in early 2017.

Scintilla Pharmaceuticals is currently a subsidiary of Sorrento Therapeutics. Scintilla's lead program is RTX for the treatment of opiate refractory cancer pain. The RTX program has been tested successfully in a Phase 1 - 2 clinical trial, and is sc...Show all

See All Exits Recent Exits

Scintilla Pharmaceuticals - Investments & Acquisitions

Show Real Data Scintilla Pharmaceuticals Investments
See all Recent Investments
Date Company Round Amount Co-investors
2016-08-16Semnur PharmaceuticalsAcquired
See all 1 investments